Results 91 to 100 of about 22,097 (178)

Mumps Outbreak in Shivamogga, India (2023-2024): Age-Specific Attack Rates, Complications, and an Economic Case for Measles-Mumps-Rubella Vaccine Inclusion in the Universal Immunization Programme. [PDF]

Cureus
Gireesh S, Sakaleshpur Kumar V, S R R.
europepmc   +1 more source

Measles-rubella vaccine-associated MOG-antibody positive acute demyelinating encephalomyelitis with optic neuritis in a child. [PDF]

Ther Adv Vaccines Immunother, 2022
Otiv M, Botre A, Shah P.
europepmc   +1 more source

High measles and rubella vaccine coverage and seroprevalence among Zambian children participating in a measles and rubella supplementary immunization activity. [PDF]

PLOS Glob Public Health
Prosperi C, Truelove S, Carcelen AC, Chongwe G, Mwansa FD, Ndubani P, Simulundu E, Bwalya IC, Hamahuwa M, Kapungu K, Matakala KH, Musukwa G, Mutale I, Betha E, Chaavwa N, Kampamba L, Matoba J, Munachoonga P, Mufwambi W, Situtu K, Thuma PE, Sakala C, Kayeye P, Winter AK, Ferrari MJ, Moss WJ, Mutembo S.   +26 more
europepmc   +1 more source

Corrigendum to "Examination of scenarios introducing rubella vaccine in the Democratic Republic of the Congo" [Vaccine: X 9 (2021) 100127]. [PDF]

Vaccine X, 2022
Cheng A, Frey K, Mwamba GN, McCarthy KA, Hoff NA, Rimoin AW.   +5 more
europepmc   +1 more source

Estimated Current and Future Congenital Rubella Syndrome Incidence with and Without Rubella Vaccine Introduction - 19 Countries, 2019-2055. [PDF]

MMWR Morb Mortal Wkly Rep
Lebo E, Vynnycky E, Alexander JP, Ferrari MJ, Winter AK, Frey K, Papadopoulos T, Grant GB, O'Connor P, Reef SE, Crowcroft NS, Zimmerman LA.   +11 more
europepmc   +1 more source

Prediction of Specific Antibody- and Cell-Mediated Responses Using Baseline Immune Status Parameters of Individuals Received Measles-Mumps-Rubella Vaccine. [PDF]

Viruses, 2023
Toptygina A, Grebennikov D, Bocharov G.
europepmc   +1 more source

Comparative Immunogenicity and Safety of Measles-Mumps-Rubella Vaccine When Administered Using Needle Free Injection System to That with Conventional Needle-Syringe in India: A Randomized, Parallel Group Study. [PDF]

Med Devices (Auckl)
Ratta BS, Naik A, Mutha S.
europepmc   +1 more source

Examination of scenarios introducing rubella vaccine in the Democratic Republic of the Congo. [PDF]

Vaccine X, 2021
Cheng A, Frey K, Mwamba GN, McCarthy KA, Hoff NA, Rimoin AW.   +5 more
europepmc   +1 more source

Immunogenicity and Safety Results of a Randomized, Three-Arm, Phase IV Clinical Trial of Concomitant Administration of Typhoid Vi Conjugate Vaccine with Measles and Rubella Vaccine in Healthy Infants. [PDF]

Viruses
Rao SN, Ambike D, Patil M, Mankar SV, Verma N, Hanumante N, Sarangi L, Mitra M, Preeti G, Deshmukh BJ, Nanoti G, Faridi MMA, Daultani P, Mittal R, Maithal K, Kansagra K, Parmar DV, Kunnathamman R, Elaiyaraja M, Dutta T, Mahajan M, Desai S.   +21 more
europepmc   +1 more source

Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial. [PDF]

Vaccines (Basel), 2023
Baker B, Bermingham IM, Leelasena I, Hickling J, Young PR, Muller DA, Forster AH.   +6 more
europepmc   +1 more source